MRD-Guided Elranatamab Maintenance Therapy
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 65 patients (estimated)
- Sponsors
- Washington University School of Medicine
- Collaborators
- Pfizer, National Comprehensive Cancer Network, Rapid Novor
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3, Maintenance, Post-Autologous Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1969
- NCT Identifier
- NCT06483100
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.